FDA Brief

Company record

Slate Run Pharmaceuticals

0 FDA warning letters since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about Slate Run Pharmaceuticals.

Recalls

ReportedClassFirmProduct and reason
Mar 4 Class III Slate Run Pharmaceuticals
Drug
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Are…
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
FDA notice D-0343-2026